NCT01840774

Brief Summary

The purpose of this study is to determine how pain relief is modified when the investigators combine the Virtual Reality based Snow World game with certain pain medications.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2013

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

April 8, 2013

Completed
18 days until next milestone

First Posted

Study publicly available on registry

April 26, 2013

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

April 26, 2013

Status Verified

April 1, 2013

Enrollment Period

1.2 years

First QC Date

April 8, 2013

Last Update Submit

April 25, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain responses between placebo and the low-dose pain medication while playing Snow World. We will assess pain responses with subjective questionnaires concerning the participant's experience while playing Snow World.

    Conclusion of 120 study visits. Each participant will spend a total of 8 hours with us.

Study Arms (2)

Low-dose pain medication

ACTIVE COMPARATOR

80min IV infusion of a low-dose pain medication

Drug: Low-dose pain medication (Ketalar) and saline placebo

saline placebo

PLACEBO COMPARATOR

80min IV infusion of a saline placebo

Drug: Low-dose pain medication (Ketalar) and saline placebo

Interventions

Low-dose pain medicationsaline placebo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy male and females between the age of 18 and 60 years
  • Ability to communicate orally
  • Ability to read and understand English
  • Body Mass Index between 20-35

You may not qualify if:

  • Women who are pregnant, trying to become pregnant, or who are breastfeeding
  • History of alcohol or substance abuse
  • Major medical illness; including history of migraine headaches, seizures, brain injury, or peripheral neuropathy
  • Current use of analgesics including acetaminophen, non-steroidal anti-inflammatories, or opioids
  • Predisposition to severe motion sickness
  • Unusual sensitivity or lack of sensitivity to pain
  • Urine toxicology positive for opioids or benzodiazepines

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Washington

Seattle, Washington, 98195, United States

RECRUITING

MeSH Terms

Interventions

AcetaminophenKetamine

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbons

Study Officials

  • Samuel Sharar, MD

    University of Washington

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christine Hoffer, BA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Study Principal Investigator

Study Record Dates

First Submitted

April 8, 2013

First Posted

April 26, 2013

Study Start

April 1, 2013

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

April 26, 2013

Record last verified: 2013-04

Locations